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Abstract
We mapped ∼85,000 rare nonsynonymous exonic single nucleotide polymorphisms (SNPs) to 17 psychophysiological
endophenotypes in 4,905 individuals, including antisaccade eye movements, resting EEG, P300 amplitude, electrodermal
activity, affect-modulated startle eye blink. Nonsynonymous SNPs are predicted to directly change or disrupt proteins
encoded by genes and are expected to have significant biological consequences. Most such variants are rare, and new
technologies can efficiently assay them on a large scale. We assayed 247,870 mostly rare SNPs on an Illumina exome
array. Approximately 85,000 of the SNPs were polymorphic, rare (MAF < .05), and nonsynonymous. Single variant
association tests identified a SNP in the PARD3 gene associated with theta resting EEG power. The sequence kernel
association test, a gene-based test, identified a gene PNPLA7 associated with pleasant difference startle, the difference
in startle magnitude between pleasant and neutral images. No other single nonsynonymous variant, or gene-based group
of variants, was strongly associated with any endophenotype.
Descriptors: Endophenotype, Psychophysiology, Exome, Rare variant, Nonsynonymous, GWAS, P300, Startle,
Antisaccade, Electrodermal, EEG
Endophenotypes have been widely proposed as useful targets for
genetic association studies (Gottesman & Gould, 2003). Typically,
endophenotypes are conceptualized as measures of psychological
and biological processes relevant to a clinical phenotype of interest.
In the causal chain from genes to disorder, endophenotypes are
thought to occupy an intermediate location more directly influenced
by genetic variants, which in principle makes them attractive for
identifying genes that influence the clinical phenotype. In the
current manuscript, we focus on identifying rare genetic variants in
DNA that might be associated with such endophenotypes. We
describe genetic association results for 17 psychophysiological
endophenotypes, including antisaccade eye movements, measures
of the resting electroencephalogram (EEG), amplitude of the P300
wave of the event-related potential, measures of electrodermal activ-
ity, and affect-modulated startle eye blink. To varying degrees, many
of these measures have long been considered putative endophe-
notypes for disinhibitory psychopathology, substance misuse and
dependence, schizophrenia, mood disorders, and other disorders.
The results presented here complement results of the genome-wide
association studies (GWAS) of these endophenotypes, which are
described in the accompanying common variant articles in this
special issue (Malone, Burwell et al., 2014; Malone, Vaidyanathan
et al., 2014; Vaidyanathan, Isen et al., 2014; Vaidyanathan, Malone,
Donnelly et al., 2014; Vaidyanathan, Malone, Miller, McGue, &
Iacono, 2014). Detailed background information about the
psychophysiological measures and their heritability is available in
these other articles, which we summarize briefly here.
In these accompanying five common variant articles in
this special issue, genetic association tests between these
endophenotypes and common single nucleotide polymorphisms
(SNPs that occur greater than 5% of the time) yielded few genome-
wide significant findings. Antisaccade error was significantly
associated with one SNP, located on Chromosome 2. Likewise, an
aversive-neutral startle modulation difference score produced
several subthreshold associations for SNPs in a small region of
Chromosome 3, which are in linkage disequilibrium (LD) with
each other, and therefore correlated. Gene-based analyses, in
which effects for all SNPs within a gene are aggregated into a
single gene-based score and tested for association with an
endophenotype, yielded evidence of significant association with
several endophenotypes. EEG low-frequency (delta) power was
associated with a GABAA receptor gene and two others not plau-
sibly related to brain activity. Antisaccade performance was
associated with two genes on Chromosome 2—B3GNT7 and
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NCL—while the aversive-neutral modulation difference score was
associated with the PARP14 gene on Chromosome 3.
At the same time, SNP heritability analyses of the additive
aggregate effect of all available common variants on the Illumina
660W-Quad genotyping array, or variants in LD with them,
account for an appreciable amount of variance in each
endophenotype. That is, there is clearly a genetic signal on the
array even if these five individual GWA studies did not identify any
individual locus. In addition, the SNP-based heritability does not
recapture all of the heritability estimated through the twin design,
suggesting that common variants do not explain all of the heritabil-
ity of these endophenotypes. The idea that common SNPs only
capture part of the genetic variance in a population is by now
commonplace in psychiatric genetics, and has led many to consider
the potential role of rare variants.
No study has yet systematically evaluated the role of rare vari-
ants in any of the endophenotypes considered in this special issue.
Functional variants, such as nonsynonymous SNPs, are more likely
to disrupt gene function, more likely to be rare (Tennessen et al.,
2012), and are hypothesized to have greater expected impact on
phenotypic development than other variants. Nonsynonymous vari-
ants are exonic, lying in the coding regions of genes, and are
predicted to disrupt the gene’s coding sequence, resulting in mal-
formed and dysfunctional protein products. A nonsynonymous
variant in a critical place, such as a variant that changes an amino
acid to a stop codon sequence, can cause a gene to produce a
malformed protein, or no protein at all, and result in significant
consequences for the organism as a whole. What is more, rare
variants arose relatively recently in human evolution and are
largely independent of the common variants that are most often
assayed in GWAS. Therefore, the potentially causal rare variants
investigated in the present article would have been missed by
previous genome-wide studies, including those described in the
accompanying five common variant articles of this special issue.
The increasing use of exome sequencing has made the discov-
ery of rare exonic variants possible and even efficient. Exome
chips, available from Affymetrix or Illumina, were created to
genotype rare variants discovered in exome sequences from 16
studies of 12,000 total individuals. Using this sequence informa-
tion, the chip was designed to assay ∼250,000 nonsynonymous
variants across the exome (http://genome.sph.umich.edu/wiki/
Exome_Chip_Design). In the present study, we used the Illumina
HumanExome BeadChip to assay rare nonsynonymous variants
across the genome.
An inherent difficulty in the study of rare variants is that, by
definition, very few people carry them. While only one carrier of a
mutation is necessary to discover the existence of that variant, it is
impossible to draw strong statistical conclusions in a single indi-
vidual about the association of that variant with any phenotype. To
identify many individuals who carry some rare variant requires
very large sample sizes or specialized designs (e.g., extreme phe-
notypes, carrier pedigrees). For example, if a variant is present in
only 1 in 10,000 individuals, one must genotype DNA from
100,000 individuals just to find 10 people who carry that variant. In
response to this problem, the past few years have seen many new
methods developed specifically for the analysis of rare variants
(Asimit & Zeggini, 2010; Lee, Abecasis, Boehnke, & Lin, 2014).
Perhaps the most intuitive approach is to collapse (e.g., sum) across
all rare variants within a gene (called a “burden” test) and regress
the phenotype on that sumscore. In the present study, we apply two
complementary approaches to collapsing rare variants. First, we
summed the total number of minor alleles within a given gene and
tested for an association between an endophenotype and the gene
sumscore (i.e., the variable threshold collapsing and multivariate
count burden test [Li & Leal, 2008; Price et al., 2010]). This test
suffers from low power when variants within a gene have opposite
directions of effect. To overcome this potential issue, we also used
the sequence kernel association test, or SKAT (Wu et al., 2011),
which uses a different statistical approach to allow for variants
within a gene to have different directions of effect.
In summary, we systematically evaluated the role of
nonsynonymous exonic variants in ∼4,000 individuals for 17
endophenotypes. We conducted association tests for individual
SNPs, as well as gene-based burden tests. The present study is the
largest single study of its kind and the first to comprehensively
evaluate the role of rare nonsynonymous variants with
psychophysiological endophenotypes.
Methods
Participants
All participants were from the Minnesota Center for Twin and
Family Research (MCTFR; Iacono, McGue, & Krueger, 2006).
The full MCTFR study was genotyped, but the association analyses
described here were conducted only on those individuals who
participated in a psychophysiology laboratory assessment: the two
age cohorts of the Minnesota Twin Family Study (MTFS; Iacono &
McGue, 2002) and the enrichment sample (ES; Keyes et al., 2009).
See the accompanying methodological overview (and Figures 1
and 4 of that article) for a detailed description of the sample and
study design (Iacono, Malone, Vaidyanathan, & Vrieze, 2014).
Endophenotypes
Details about each endophenotype are available in this special
issue’s methodological overview (Iacono et al., 2014) and in each
of the five common variant research articles. We evaluated 17
endophenotypes in all:
• P300 amplitude reduction (Malone, Vaidyanathan et al., 2014):
1. P3 event-related potential (P3; N = 4,166)
2. P3 genetic factor (gP3; N = 3,088)
• Antisaccade tracking error rate (Vaidyanathan, Malone,
Donnelly et al., 2014)
3. Antisaccade tracking error rate (SAC; N = 4,469)
• Electrodermal activity (Vaidyanathan, Isen et al., 2014)
4. Skin conductance level (SCL; N = 3,791)
5. Skin conductance response frequency (fSCR; N = 4,299)
6. Skin conductance response amplitude (aSCR; N = 4,102)
7. Electrodermal activity factor (EDA; N = 4,424), a general
factor derived from SCL, fSCR, and aSCR
• Affective startle modulation (Vaidyanathan, Malone, Miller
et al., 2014)
8. Overall startle (STRTL; N = 3,323)
9. Aversive difference startle (aSTRTL; N = 3,321)
10. Pleasant difference startle (pSTRTL; N = 3,322)
• Resting state EEG (Malone, Burwell et al., 2014)
11. Total EEG power (totPower; N = 3,948)
12. Alpha EEG power (αPower; N = 3,948)
13. Beta EEG power (βPower; N = 3,948)
14. Theta EEG power (θPower; N = 3,948)
15. Delta EEG power (δPower; N = 3,948)
16. Alpha EEG power O1O2 (αPowerO1O2; N = 3,966)
17. Alpha EEG frequency O1O2 (αFreqO1O2; N = 3,966)
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Covariate Correction and Inverse Normalization
All endophenotypes were corrected for sex, chronological age,
generational status (parent vs. child) and, when relevant, task-
specific laboratory covariates. To account for population stratifica-
tion and familial relatedness, we opted to use an empirical kinship
linear mixed model approach (described below) instead of princi-
pal components. In addition, rare variant analyses can be highly
sensitive to outliers, and non-normality of the phenotypic distribu-
tion which, given the small effects of genetic variants, is also very
close to the residual distribution. Therefore, all endophenotypes
were inverse normalized after covariate correction and prior to the
association analysis. This approach reduces false positives by sim-
ultaneously eliminating non-normality and pulling in phenotypic
outliers.
Genotypes
A total of 4,905 individuals in the MCTFR participated in labora-
tory psychophysiological testing. To improve genotype quality for
the subset of individuals who participated in the genotype lab, we
conducted genotype quality control using genotypes on the full
sample. From the available MCTFR sample, 7,350 individuals
(note this number includes only one member of each monozygotic
[MZ] twin pair) were genotyped on both the Illumina
HumanExome-12v1_A array and the Illumina 660W-Quad. A
detailed description of quality control for the 660W-Quad is avail-
able in a prior publication (Miller et al., 2012) and in the methodo-
logical overview for this special section.
The Illumina HumanExome BeadChip includes 247,870 mostly
rare single nucleotide variants (85.0% of variants have a minor
allele frequency less than 1%). All 7,350 samples genotyped on this
chip were clustered into the three allele groups possible for each
SNP (AA, AB, and BB) using GenomeStudio (Illumina, San
Diego, CA) and then imported in the GENVISIS genetic visuali-
zation software (Pankratz, 2014). Multiple quality control (QC)
steps used the theta transformation, which is simply a transforma-
tion of the genotype intensity coordinates to make comparison of
the genotype intensity clusters more straightforward. Markers
showing evidence of poor quality (n = 15,741; see online support-
ing information Table S1), such as lower call rates, poor separation
between genotype clusters (mean separation less than 0.30 in the
theta dimension, representing allele frequency), evidence of
cohybridization (mean theta deviates more than 0.20 from the
expected values of 0, 0.5, and 1.0 for AA homozygotes,
heterozygotes, and BB homozygotes, respectively), large theta
standard deviations (> 0.025 for a homozygous cluster or > 0.07 for
the heterozygous cluster), excess heterozygosity (HetExcess > 0.1
or HetExcess < −0.9), rare (0 ≤ minor allele frequency
[MAF] < .0001), or monomorphic with an incomplete call rate
(< 1.0) were flagged, manually reviewed, and either reclustered
(n = 6,865) or discarded (n = 1,844). The remainder of manually
reviewed markers were not problematic and were left undisturbed.
The 246,026 variants that remained after discarding those that
could not be reclustered were carried forward for standard QC
testing in a sample of 3,259 unrelated white, non-Hispanic partici-
pants. Unrelated individuals were chosen because some QC
metrics show bias in the presence of families (e.g., Hardy-
Weinberg). A total of 422 additional markers were dropped in our
standard QC screen: 236 markers still had a call rate less than 99%,
114 had a Hardy-Weinberg test p value less than the Bonferroni
cutoff of 2e-7, 22 autosomal markers were associated with
participant sex (p < 2e-7), and 148 variants had two or more of any
of the following errors: incorrect call in a Center for the Study of
Human Polymorphisms (CEPH) sample, discordant calls in a pair
of duplicated samples or a monozygotic twin pair, Mendelian
inconsistency, heterozygosity for an X-chromosome marker in a
male sample, or nonmissing Y-chromosome genotype for a female
sample. See supporting information Table S2 for a breakdown of
why markers were flagged, reviewed, reclustered, and dropped.
This left 245,484 exome chip markers available for analyses.
After sample QC screening, we were left with usable genotype
data for 7,244 subjects, including only one member of each MZ
twin pair. Samples were dropped for a no-call rate of .5% or higher
(145 samples); 16 samples were dropped because of sample mix-
ups; 4 samples were dropped because of consent issues; and for all
duplicate samples, only the one with the highest call rate was
retained. After creating records for 1,120 MZ co-twins by copying
genotype data of their MZ twin, assuming MZ twins share 100% of
the genotypes on the exome array, the sample size usable for
GWAS increased to 8,364 subjects, including all individuals,
regardless of ethnicity.
Markers from the exome chip and genome-wide chip were
combined into an integrated panel of 674,930 polymorphic SNPs.
We used this integrated panel primarily to generate the empirical
kinship matrix for association testing, and did not consider
common SNPs in these analyses, as the companion articles from
this special issue present results for common SNP associations with
the same endophenotypes. There were 41 individuals who passed
quality control on the genome-wide chip but not the exome chip,
bringing the total sample genotyped on at least one of the two
arrays from 8,364 to 8,405. There were 99,195,810 overlapping
genotypes between the arrays in this integrated sample (11,802
overlapping SNPs × 8,405 individuals; we included the MZ
co-twins in these numbers). Of these, 98,414,738 genotypes were
assayed and passed quality control on both chips (99.2%). Of these,
98,405,631 (99.9908%) were concordant. The 9,107 discordant
genotypes were set to missing and not used in the association
analyses.
Nonsynonymous SNPs were identified and annotated with
EPACTS (Kang, 2014) using GENCODE v11 transcripts (Harrow
et al., 2012). To annotate a SNP, one determines whether an allele
of the SNP would result in an amino acid change or splicing
disruption in one or more known transcripts.
Out of the final sample of 8,405 (for 41 of whom, rare exonic
variants were available only from the Illumina 660W-Quad array),
4,905 had data on at least one psychophysiological index that is
part of this study. These 4,905 subjects were utilized in the analyses
described below.
Association Analysis
To correct for within-family correlation and population stratifica-
tion, we used the EMMAX (Kang et al., 2010) approach as imple-
mented in EPACTS (Kang, 2014). EMMAX uses a linear mixed
model and an empirical kinship matrix to correct simultaneously
for familial resemblance and population stratification (Listgarten
et al., 2012). Empirical kinships are calculated from the genotype
information, and represent the degree of blood relation, or consan-
guinity, between individuals in the study. For single variant tests we
restricted analysis, and our correction for multiple testing, to vari-
ants with minor allele counts greater than 4 and minor allele fre-
quency less than 5%. The former restriction is useful because our
study does not have sufficient power to detect effects with lower
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minor allele frequencies, and the asymptotics of our statistical tests
break down when minor allele counts are extremely low. The latter
restriction is appropriate because we already comprehensively test
common SNPs in the accompanying common variant articles in
this special issue.
In addition to single variant tests using a score test, we also
conducted two gene-based burden tests of nonsynonymous variants
with MAF < .05. The first gene-based burden test was the variable
threshold collapsing and multivariate count method, or VTCMC
(Li & Leal, 2008; Price et al., 2010). VTCMC sums minor alleles
for rare variants within a gene and tests for association between that
sum and the endophenotype. The threshold for considering which
variants are rare, and therefore included in the sum, is evaluated
from the data. The threshold that minimizes the resulting p value is
used. To avoid capitalizing on chance in selecting the optimal
threshold and conducting statistical tests in the same data, we used
permutation to arrive at unbiased p values. One limitation of the
VTCMC approach is that it has greatest power when all variants
within a gene have the same direction of effect (e.g., the rare allele
always increases the endophenotype value). If rare alleles within a
gene have opposite directions of effect, then VTCMC and related
approaches lose power to detect effects.
Other statistical tests have been developed to allow for different
directions of effect within a gene, and we use an implementation of
SKAT (Wu et al., 2011) to complement the VTCMC approach.
SKAT is essentially a variance component test, as it tests whether
the distribution of SNP effects within a gene are overdispersed
(larger than expected by chance), regardless of whether they are
positive or negative.
We evaluated 204 candidate genes in more detail. These were
selected from the NeuroSNP database (https://zork5.wustl.edu/
nida/neurosnp.html) for their potential relevance to the
endophenotypes examined here or their associated clinical pheno-
types. Genes within this candidate set are known either to play a
role in the major neurotransmitter or neuromodulatory systems
(acetylcholine, dopamine, noradrenaline, serotonin, glutamate,
GABA), to be involved in metabolizing alcohol and nicotine, or to
be part of the endogenous opioid and cannabinoid systems. See the
methods article in this special issue for more information about
these candidate genes (Iacono et al., 2014).
For any significant single variant results, we further annotated
SNPs using combined annotation dependent depletion (CADD;
Kircher et al., 2014). CADD annotates variants with a variety of
algorithms, including the variant effect predictor (VEP; McLaren
et al., 2010), PolyPhen2 (Adzhubei et al., 2010), and sorting intol-
erant from tolerant (SIFT; Kumar, Henikoff, & Ng, 2009). A useful
aspect of CADD is that it attempts to incorporate these and other
annotation information to develop a single, integrated score for
every possible single nucleotide mutation in the human genome.
The algorithm used in CADD is a support vector machine (SVM),
a supervised learning approach that uses known positive and nega-
tive examples of pathogenic variants to score novel variants as
deleterious. CADD produces a C-score, which is a phred scaled
score (phred = −10 × log10(percentile rank/100)) of the SVM pre-
diction. For example, a score of 20 is in the 10th percentile of
predicted deleteriousness, 30 in 1st percentile, and 40 in the 0.1st
percentile.
Results
See Tables 1 and 2 and Figure 2 in Iacono et al. (2014) for descrip-
tive statistics of, and correlations among, the 17 endophenotypes.
Significant clustering was observed within skin conductance meas-
ures, startle, the two measures of P3, and EEG power. The full
correlation matrix for the residualized endophenotypes is provided
in Table S3 and displayed graphically in Figure 2 of the methods
article of this special issue (Iacono et al., 2014).
First, we tested for endophenotype associations with rare indi-
vidual SNPs. Sample sizes for each endophenotype are listed in
Table 1 of Iacono et al. (2014). Genomic control ranged from .99 to
1.04 considering only nonsynonymous variants with MAF < .05,
suggesting minimal influence of statistical artifacts on our rare
variant tests. The number of nonsynonymous variants with minor
allele count (MAC) ≥ 5 and MAF < 5% ranged from 38,818 (P3
genetic factor) to 46,774 (antisaccade), resulting in per-
endophenotype Bonferroni corrections from 1.29 × 10−6 to
1.07 × 10−6, respectively. At these levels of significance, one SNP
was associated with significantly higher theta EEG power (β = 1.2,
R2 = .6%, p = 9.5 × 10−7). The SNP is rs139550735, which is
nonsynonymous with MAC of 19 (MAF = .0024), located at Chro-
mosome 10, position 34,671,513 of the GRCh37 reference
genome, with reference allele T and alternate allele C, and lies in
the Par-3 family cell polarity regulator gene (PARD3). PolyPhen2
annotated the variant as “benign.” SIFT annotated it as “tolerated.”
The phred-scaled CADD score was 15.21, indicating that this
variant is ranked in the 3rd percentile for pathogenicity. Since the
variant is rare, only a few individuals carry it, and we display theta
EEG power for each family containing an individual carrying this
SNP in Figure 1, which simply shows the pattern of theta EEG
power in those family members who carry the rare variant and
those who do not. The rs139550735 variant has been described
previously in both the 1000 Genomes project and the Exome
Sequencing Project. The variant had MAF = .002 in the Exome
Sequencing Project, with the minor allele observed 17 times in
4,283 individuals of European ancestry in that project. These fre-
quency estimates are highly consistent with ours. Q-Q plots and
Manhattan plots for each endophenotype are available in the sup-
porting information.
Next, we examined VTCMC burden test association between
the endophenotypes and all genes with sufficient nonsynonymous
variation (i.e., gene contains nonsynonymous SNPs with
MAF < .05 and has a burden allele count of 3 or more). Sample
sizes for the burden tests were the same as those for single variant
tests (see Methods), and the number of genes with sufficient
nonsynonymous variation ranged from 14,330 (P3 genetic factor)
to 14,859 (antisaccade). This resulted in per-endophenotype
Bonferroni corrections of 3.4 × 10−6 and 3.5 × 10−6, depending on
the number of genes tested for each phenotype. The top VTCMC-
associated genes for each endophenotype are displayed in Table 1.
At these levels of significance, no gene was significantly associated
with any endophenotype. The PARD3 gene was the second-most
significant gene for theta power EEG (p = 7.1 × 10−5, nonsignifi-
cant), but this was driven entirely by the single significant SNP
rs139550735 reported in the previous paragraph.
We conducted a similar analysis using the complementary
SKAT gene-based test. We again evaluated genes containing SNPs
with MAF < .05 and burden allele count ≥ 3. The SKAT test iden-
tified a single gene (see Table 2) as significantly associated with
pleasant difference startle (pSTRTL; p value = 1.6 × 10−6). The
gene, patatin-like phospholipase domain containing 7 (PNPLA7),
has been implicated in adipocyte differentiation and lipid metabo-
lism (Wilson, Gardner, Lambie, Commans, & Crowther, 2006). To
better understand the individual variants that comprise the signifi-
cant SKAT results, we display single variant results for all
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nonsynonymous variants within PNPLA7 in Table 3. It appears that
the SKAT result is driven by two low-frequency variants with
opposite directions of effect within the gene. Additional CADD
annotation suggests that these particular variants are not highly
deleterious.
Finally, we evaluated in more detail the 204 genes in our can-
didate gene set. Depending on the endophenotype, 157–159 genes
possessed sufficient nonsynonymous variation to be considered
(more than one variant, burden allele count of 3 or more). No
gene-based test was significant even when relaxing the Bonferroni
significance threshold to account for 159 genes (p < .00032). The
most significant gene identified by the VTCMC method was
ALDH3B2 associated with alpha EEG power at O1O2 with
p = .0007. The most significant gene for SKAT was total EEG
power with SLC6A17 at p = .0008.
Discussion
The psychophysiological endophenotypes reported here include
basic measures of brain activity (resting EEG) as well as those
tapping fundamental reflexes like the startle eye blink and habitu-
ation of the electrodermal orienting response. Each is of particular
interest as a possible endophenotype for a variety of psychopathol-
ogy constructs. In the end, we tested 17 psychophysiological meas-
ures for association with ∼85,000 exome-wide nonsynomyous
SNPs from the Illumina HumanExome array. One SNP was sig-
nificantly associated with theta EEG power. One gene, PNPLA7,
was significantly associated with pleasant difference startle, or the
difference in startle magnitude between pleasant and neutral
images. None of our proposed candidate genes were significantly
associated with any endophenotype, by either of the gene-based
tests employed here.
The single SNP associated with theta EEG power is
nonsynonymous in the PARD3 gene. This gene is involved in cell
polarity regulation, expressed in the brain, and thus appears bio-
logically plausible. A recent study reported an association between
PARD3 and schizophrenia (Kim, Lee, Park, Kim, & Chung, 2012),
which is sometimes associated with increased theta power (Begic
et al., 2011; Clementz, Sponheim, Iacono, & Beiser, 1994; Harris,
Melkonian, Williams, & Gordon, 2006; Sponheim, Clementz,
Iacono, & Beiser, 1994, 2000; Sponheim, Iacono, Thuras, Nugent,
& Beiser, 2003). Increased theta power is also a robust correlate of
attention deficit hyperactivity disorder (ADHD; Barry, Clarke, &
Johnstone, 2003), and it has been observed in adults with various
forms of disinhibitory psychopathology, such as alcoholism, mari-
juana use, and antisocial behavior as well (Ehlers, Phillips, Gizer,
Table 1. Top 2 Genes for Each Endophenotype with Most Significant VTCMC Associations
Endophenotype Gene Chr
No. SNPs with
MAF < .05
Burden AC
for SNPs with
MAF < .05
Optimal
burden
MAC R2 (%) Direction
Bonferroni
correction p value
P3 TRIP10 19 9 20 4 .41 − 3.4e-6 1.2e-4
MADD 11 13 174 3 .41 − 3.4e-6 2.5e-4
gP3 KARS 16 8 54 21 .56 + 3.5e-6 1.3e-4
MADD 11 13 125 3 .6 − 3.5e-6 1.7e-4
SAC AFTPH 2 15 202 6 .44 + 3.4e-6 8.0e-5
ANXA3 4 8 138 104 .39 − 3.4e-6 2.3e-4
SCL DEFB116 20 2 166 163 .44 − 3.4e-6 7.3e-5
C6orf221 6 1 12 12 .39 + 3.4e-6 1.8e-4
fSCR PASK 2 23 471 25 .56 − 3.4e-6 1.2e-5
CCT6A 7 3 163 149 .47 − 3.4e-6 2.6e-5
aSCR KANK4 1 14 929 3 .53 − 3.4e-6 2.2e-5
SPAST 2 4 80 2 .48 − 3.4e-6 3.1e-5
EDA ZNF691 1 2 10 6 .40 − 3.4e-6 5.5e-5
KANK4 1 14 998 3 .44 − 3.4e-6 6.4e-5
STRTL FBX022 15 2 21 2 .48 − 3.5e-6 1.2e-4
RAET1L 6 2 14 2 .48 − 3.5e-6 1.2e-4
aSTRTL ANKRD13C 1 2 35 7 .50 − 3.5e-6 8.1e-5
KCNA3 1 2 28 27 .48 − 3.5e-6 1.6e-4
pSTRTL SIL1 5 5 69 3 .69 + 3.5e-6 7.0e-6
BAI2 1 7 141 22 .67 + 3.5e-6 1.6e-5
αPower C17orf57 17 10 779 6 .59 − 3.4e-6 1.0e-5
OR5H2 3 7 125 52 .57 + 3.4e-6 1.2e-5
βPower GTPBP3 19 4 228 1 .48 − 3.4e-6 3.4e-5
C9orf9 9 2 5 4 .47 − 3.4e-6 4.1e-5
θPower MICAL2 11 23 189 27 .59 + 3.4e-6 1.2e-5
PARD3 10 10 98 19 .49 + 3.4e-6 7.1e-5
δPower FASN 17 25 684 10 .54 + 3.4e-6 5.4e-5
EDC4 16 6 91 18 .42 − 3.4e-6 1.8e-4
totPower FASN 17 25 684 10 .49 + 3.4e-6 1.2e-4
OCEL1 19 2 3 2 .41 − 3.4e-6 1.5e-4
αPowerO1O2 TFPI2 7 2 16 2 .44 − 3.4e-6 1.3e-4
GTSF1 12 1 13 13 .34 − 3.4e-6 2.3e-4
αFreqO1O2 RNF175 4 7 203 49 .54 − 3.4e-6 2.1e-5
SMAD1 4 2 5 3 .44 + 3.4e-6 4.3e-5
Note. All endophenotype abbreviations are defined in the text. Genes with a burden allele count < 3 were not considered in arriving at these Bonferroni
corrections. VTCMC = variable threshold collapsing and multivariate count burden test (Price et al., 2010); MAF = minor allele frequency; MAC = minor
allele count; R2 = coefficient of determination, in this case variance accounted for in residualized, inverse-normalized endophenotype.
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Gilder, & Wilhelmsen, 2010; Rangaswamy et al., 2003; Struve
et al., 1999). The companion sequencing article (Vrieze et al.,
2014) found a p value of .013 for this same variant in 1,045
whole-genome-sequenced individuals (MAF = .002; MAC = 5),
and a p value of 1.2 × 10−6 after imputation into the full sample of
3,948 individuals with values for this measure. The participants in
the exome chip and sequencing studies are the same, so this is by
no means an independent replication. It simply shows that a distinct
genotyping approach reproduced the finding. PARD3 has also not
been identified in previous studies of psychophysiological
endophenotypes, and thus we urge replication of this finding in
other data, as well as caution in interpreting the implications.
The SKAT gene-based test identified PNPLA7 as significantly
associated with pleasant difference startle, which represents the
degree to which startle eye blink is attenuated by pleasant stimuli.
Judging by the single variant tests reported in Table 3, the SKAT
association appears to be driven by two nonsynonymous variants
within PNPLA7 that have opposite directions of effect. PNPLA7
has been implicated in adipocyte differentiation and lipid metabo-
lism (Wilson et al., 2006), as well as for neurological health,
particularly neuropathy (Richardson, Hein, Wijeyesakere, Fink, &
Makhaeva, 2013), but has no obvious biological connection to
startle psychophysiology. Using the same criteria for a
nonsynonymous variant, the companion sequencing article (Vrieze
et al., 2014) discovered 26 SNPs within PNPLA7 in 840 individ-
uals and found a SKAT p value of .05. After imputation into the full
sample of 3,322, the same article discovered 28 SNPs that met
criteria and found a SKAT p value of 9.5 × 10−6. This is not an
independent replication, but does suggest mild stability in the
PNPLA7 effect in this sample across two genotyping approaches.
We welcome independent replication of this finding.
In the companion GWAS paper on startle (Vaidyanathan,
Malone, Miller et al., 2014), we obtained a significant association
for PARP14 with modulated startle, but for aversive difference
startle. The biometric and GCTA analyses included in that paper
found neither of the two modulated startle measures were heritable.
While this alone does not preclude the possibility of a rare variant
association, it does not increase confidence in any genetic
Table 2. Top Two Genes for Each Endophenotype with Most
Significant SKAT Associations
Endophenotype Gene Chr
No. SNPs with
MAF < .05
Bonferroni
correction p value
P3 BIN3 8 2 3.4e-6 4.9e-5
TRIP10 19 9 3.4e-6 6.9e-5
gP3 KARS 16 8 3.5e-6 7.7e-5
ZNF560 19 10 3.5e-6 9.1e-5
SAC ANXA3 4 8 3.4e-6 1.2e-5
GALM 2 4 3.4e-6 4.3e-5
SCL DEFB116 20 2 3.4e-6 1.0e-5
C6orf221 6 1 3.4e-6 1.1e-4
fSCR CCT6A 7 3 3.5e-6 9.2e-6
FAM180A 7 2 3.5e-6 3.3e-5
aSCR RNF126 19 4 3.5e-6 1.0e-4
MEPE 4 6 3.5e-6 1.1e-4
EDA ZNF691 1 2 3.4e-6 3.6e-5
DEFB116 20 2 3.4e-6 4.1e-5
STRTL GRID2IP 7 4 3.4e-6 3.0e-5
PAPSS1 4 4 3.4e-6 6.0e-5
aSTRTL KCNA3 1 2 3.4e-6 6.7e-5
C1orf43 1 2 3.4e-6 1.6e-4
pSTRTL PNPLA7 9 22 3.5e-6 1.6e-6
PHF1 6 2 3.5e-6 5.7e-5
αPower OR5H2 3 7 3.4e-6 1.0e-5
HSPB3 5 3 3.4e-6 9.3e-5
βPower C9orf9 9 2 3.4e-6 1.9e-5
SPINT1 15 11 3.4e-6 3.7e-5
θPower CD5L 1 5 3.4e-6 8.0e-5
OCEL1 19 2 3.4e-6 9.6e-5
δPower ACOT13 6 2 3.4e-6 3.1e-4
KRIT1 7 3 3.4e-6 3.5e-4
totPower OCEL1 19 2 3.4e-6 9.0e-5
HSPB3 5 3 3.4e-6 2.2e-4
αPowerO1O2 CALCOCO2 12 6 3.4e-6 8.8e-5
ATF7IP2 16 6 3.4e-6 9.0e-5
αFreqO1O2 SMAD1 4 2 3.4e-6 3.8e-5
C15orf2 15 13 3.4e-6 7.3e-5
Note. All abbreviations are defined in Table 1. Genes with a burden allele
count < 3 were not considered in arriving at this Bonferroni correction.
SKAT = sequence kernel association test (Wu et al., 2011).
Figure 1. Theta EEG power within each of the 14 families carrying SNP
rs139550735. Bars are grouped within family. Carriers of the rare allele
(heterozygotes) are in gray, individuals who do not carry the rare allele
(homozygote for the reference allele) are in black. All families show a
consistent direction of effect except for Family 7, where the sibling with the
rare allele has lower theta power than the sibling without the rare allele.
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association finding for either modulated startle phenotype. In addi-
tion, although aversive difference startle has been associated with
psychopathology, to our knowledge, pleasant difference startle
examined alone has not. For laboratory protocols using slides
drawn from the International Affective Picture System (Lang,
Bradley, & Cuthbert, 1999) set we used here, the two measures are
examined together, and typically variation in the pattern of modu-
lated startle becomes the interpretative focus. Here, however, for
each startle component examined in isolation, we are finding dif-
ferent and unrelated associations for genes with uncertain function.
Taken together, these observations, in the absence of replication,
further reduce confidence in the genetic findings.
Clearly, no single nonsynonymous variant, or gene-based group
of variants, was strongly and indisputably associated with any
psychophysiological measure. We had expected rare variants to
affect these endophenotypes for two reasons. First, all but two of
the endophenotypes are heritable based on the twin models
reported in the companion common variant articles of this special
issue. Second, also reported in the companion common variant
articles, estimates of the aggregate effect of common variants (by
the GCTA method) was typically less than the twin-based herit-
ability, implicating the role of other classes of variants on these
endophenotypes, such as rare variants.
Limitations and Future Directions
The nonsynonymous variants tested here are but a small fraction of
all variants in the exome, which itself comprises at most 2% of
the entire genome, leaving more than 99% of rare variants in
these individuals untested by our analyses. This is because the
exome chip is a fixed array, in that it genotypes only known
nonsynonymous exonic variants based on 12,000 exome sequences.
Many nonsynonymous variants that exist in our participants are
missed on the exome array, although the obvious alternative of
exome sequencing is far more expensive than the exome chip, and
there is a balance to be struck between sample size and genotype
density.While not comprehensive, tests of nonsynonymous variants,
even from a fixed array, were a sensible starting point given their
clearly important functionality in the genome. In a companion paper
to this special issue (Vrieze et al., 2014), we report association
results using whole genome sequencing, which identifies tens of
millions additional rare variants that are tested for association with
psychophysiological endophenotypes in a subset of 1,325 MCTFR
participants. Further advances in genotype annotation continue,
such that truly deleterious variants may be more precisely identified
and included in gene-based tests in the future.
Future investigations will benefit from (a) increased sample
size, (b) broader interrogation of rare variants, and (c) additional
annotation. To increase sample size, we encourage the community
of psychophysiology investigators to pool data and resources
(Iacono & McGue, 2002). Indeed, such consortia have already
begun and published intriguing findings in relation to MRI pheno-
types (Stein et al., 2012; Thompson et al., 2014). Additional rare
variation will be discovered as genome sequencing becomes more
affordable, and functional annotation will continue to improve with
advances in epigenomics. Our use of CADD was one attempt to
leverage additional annotation to interpret our findings, but one
might imagine weighting variants within a gene according to the
C-score or other weights based on other annotation. In the end,
the present experiment identifies a handful more potential associa-
tion signals, which also require replication. Ultimately, genome
sequencing will require many additional studies with large sample
sizes to detect novel loci associated with the endophenotypes
described here. These studies will benefit from alternative research
designs and improved genotype annotation to discover and inter-
pret associated variants and genes.
Table 3. Low Frequency Nonsynonymous Variants Used in SKAT Test for Gene PNPLA7 and Pleasant Modulated Startle
Position REF ALT CADD C-score REF/HET/ALT MAF Beta (SE) p value
140357186 C T 18.41 3287/6/0 .0009 −0.061 (.41) .88
140357972 A G 0.01 0/23/3270 .0035 0.857 (.21) 5.7e-5
140358896 A T 2.87 3280/13/0 .0020 −0.123 (.28) .66
140372570 G A 15.64 3290/3/0 .0005 −0.483 (.59) .41
140372588 T C 0.09 3274/15/0 .0023 −0.048 (.26) .85
140374931 C T 2.96 3288/5/0 .0008 −0.124 (.45) .78
140391737 A G 14.51 3287/4/0 .0006 0.134 (.51) .79
140391739 G A 16.22 3292/1/0 .0002 −0.160 (1.0) .87
140392656 T C 18.80 3292/1/0 .0002 0.526 (1.0) .60
140400464 C T 10.60 3212/80/1 .0125 −0.478 (.11) 1.9e-5
140400473 G C 9.15 3284/9/0 .0014 −0.234 (.34) .49
140409842 G A 15.20 3286/7/0 .0011 −0.419 (.39) .28
140409877 C A 12.90 3287/6/0 .0009 0.284 (.42) .50
140409891 G C 11.58 3287/6/0 .0009 0.284 (.42) .50
140414411 G A 13.75 3292/1/0 .0002 1.776 (1.0) .08
140414461 C A 13.01 3291/2/0 .0003 0.447 (.72) .53
140414474 C T 12.30 3288/5/0 .0008 0.188 (.46) .68
140417222 C T 13.65 3291/2/0 .0003 0.212 (.71) .77
140437936 C T 13.76 3292/1/0 .0002 −0.792 (1.0) .43
140441299 G A 12.18 3288/5/0 .0008 1.014 (.45) .03
140441302 C A 14.32 3289/4/0 .0006 1.326 (.51) .01
140441826 G T 14.26 3292/1/0 .0002 2.325 (1.0) .02
Note. All variants were nonsynonymous missense with no stop gain/loss or start gain/loss. The CADD C-score is phred scaled (phred = −10log10(percentile
rank/100)) such that a score of 20 is in the 10th percentile of predicted deleteriousness, 30 in 1st percentile, and so on. It appears that the overall gene signal
is dominated by two low-frequency variants with opposite directions of effect. Both variants are not predicted to be highly deleterious, with C-scores of < 1
and 11. PolyPhen annotation for both variants is “benign”; similarly, SIFT annotated both variants as “tolerated.” SKAT = sequence kernel association test
(Wu et al., 2011); REF = reference allele on reference genome GRCh37; ALT = nonreference allele observed in the present study; REF/HET/ALT = number
of individuals who are homozygous for the REFerence allele, HETerozygous, and homozygous for the ALTernate allele.
1306 S.I. Vrieze et al.
References
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A.,
Bork, P., . . . Sunyaev, S. R. (2010). A method and server for predicting
damaging missense mutations. Nature Methods, 7, 248–249. doi:
10.1038/nmeth0410-248
Asimit, J., & Zeggini, E. (2010). Rare variant association analysis methods
for complex traits. Annual Review of Genetics, 44, 293–308. doi:
10.1146/annurev-genet-102209-163421
Barry, R. J., Clarke, A. R., & Johnstone, S. J. (2003). A review
of electrophysiology in attention-deficit/hyperactivity disorder:
I. Qualitative and quantitative electroencephalography. Clinical
Neurophysiology, 114, 171–183.
Begic, D., Popovic-Knapic, V., Grubisin, J., Kosanovic-Rajacic, B.,
Filipcic, I., Telarovic, I., & Jakovljevic, M. (2011). Quantitative
electroencephalography in schizophrenia and depression. Psychiatria
Danubina, 23, 355–362.
Clementz, B. A., Sponheim, S. R., Iacono, W. G., & Beiser, M. (1994).
Resting EEG in first-episode schizophrenia patients, bipolar psychosis
patients, and their first-degree relatives. Psychophysiology, 31, 486–
494.
Ehlers, C. L., Phillips, E., Gizer, I. R., Gilder, D. A., & Wilhelmsen, K. C.
(2010). EEG spectral phenotypes: Heritability and association with
marijuana and alcohol dependence in an American Indian community
study. Drug and Alcohol Dependence, 106, 101–110. doi: 10.1016/
j.drugalcdep.2009.07.024
Gottesman, I. I., & Gould, T. D. (2003). The endophenotype concept in
psychiatry: Etymology and strategic intentions. American Journal of
Psychiatry, 160, 636–645.
Harris, A., Melkonian, D., Williams, L., & Gordon, E. (2006). Dynamic
spectral analysis findings in first episode and chronic schizophrenia.
International Journal of Neuroscience, 116, 223–246. doi: 10.1080/
00207450500402977
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M.,
Kokocinski, F., . . . Hubbard, T. J. (2012). GENCODE: The reference
human genome annotation for The ENCODE Project. Genome
Research, 22, 1760–1774. doi: 10.1101/gr.135350.111
Iacono, W. G., Malone, S. M., Vaidyanathan, U., & Vrieze, S. I. (2014).
Genome-wide scans of genetic variants for psychophysiological
endophenotypes: A methodological overview. Psychophysiology, 51,
1207–1224.
Iacono, W. G., & McGue, M. (2002). Minnesota Twin Family Study. Twin
Research and Human Genetics, 5, 482–487.
Iacono, W. G., McGue, M., & Krueger, R. F. (2006). Minnesota Center for
Twin and Family Research. Twin Research and Human Genetics, 9,
978–984. doi: 10.1375/183242706779462642
Kang, H. M. (2014). Efficient and Parallelizable Association Container
Toolbox (EPACTS). Retrieved from http://genome.sph.umich.edu/wiki/
EPACTS
Kang, H. M., Sul, J. H., Service, S. K., Zaitlen, N. A., Kong, S. Y., Freimer,
N. B., . . . Eskin, E. (2010). Variance component model to account for
sample structure in genome-wide association studies. Nature Genetics,
42, 348–354. doi: 10.1038/Ng.548
Keyes, M. A., Malone, S. M., Elkins, I. J., Legrand, L. N., McGue, M., &
Iacono, W. G. (2009). The enrichment study of the Minnesota Twin
Family Study: Increasing the yield of twin families at high risk for
externalizing psychopathology. Twin Research and Human Genetics,
12, 489–501. doi: 10.1375/twin.12.5.489
Kim, S. K., Lee, J. Y., Park, H. J., Kim, J. W., & Chung, J.-H. (2012).
Association study between polymorphisms of the PARD3 gene and
schizophrenia. Experimental and Therapeutic Medicine, 3, 881–885.
Kircher, M., Witten, D. M., Jain, P., O’Roak, B. J., Cooper, G. M., &
Shendure, J. (2014). A general framework for estimating the relative
pathogenicity of human genetic variants. Nature Genetics, 46, 310–315.
doi: 10.1038/ng.2892
Kumar, P., Henikoff, S., & Ng, P. C. (2009). Predicting the effects of coding
non-synonymous variants on protein function using the SIFT algorithm.
Nature Protocols, 4, 1073–1081. doi: 10.1038/nprot.2009.86
Lang, P. J., Bradley, M. M., & Cuthbert, B. N. (1999). International affec-
tive picture system (IAPS): Technical manual and affective ratings.
Gainesville, FL: The Center for Research in Psychophysiology, Univer-
sity of Florida.
Lee, S., Abecasis, G. R., Boehnke, M., & Lin, X. (2014). Rare-variant
association analysis: Study designs and statistical tests. American
Journal of Human Genetics, 95, 5–23. doi: 10.1016/j.ajhg.2014.06.009
Li, B. S., & Leal, S. M. (2008). Methods for detecting associations with rare
variants for common diseases: Application to analysis of sequence data.
American Journal of Human Genetics, 83, 311–321. doi: 10.1016/
j.ajhg.2008.06.024
Listgarten, J., Lippert, C., Kadie, C. M., Davidson, R. I., Eskin, E., &
Heckerman, D. (2012). Improved linear mixed models for genome-wide
association studies. Nature Methods, 9, 525–526. doi: 10.1038/
nmeth.2037
Malone, S. M., Burwell, S. J., Vaidyanathan, U., Miller, M. B., McGue, M.,
& Iacono, W. G. (2014). Heritability and molecular genetic basis
of resting EEG activity: A genome-wide association study.
Psychophysiology, 51, 1225–1245.
Malone, S. M., Vaidyanathan, U., Basu, S., Miller, M. B., McGue, M., &
Iacono, W. G. (2014). Heritability and molecular genetic basis of P3
event-related brain potential amplitude: A genome-wide association
study. Psychophysiology, 51, 1246–1258.
McLaren, W., Pritchard, B., Rios, D., Chen, Y. A., Flicek, P., &
Cunningham, F. (2010). Deriving the consequences of genomic variants
with the ensembl API and SNP effect predictor. Bioinformatics, 26,
2069–2070. doi: 10.1093/bioinformatics/btq330
Miller, M. B., Basu, S., Cunningham, J., Eskin, E., Malone, S. M., Oetting,
W. S., . . . McGue, M. (2012). The Minnesota Center for Twin and
Family Research genome-wide association study. Twin Research and
Human Genetics, 15, 767–774.
Pankratz, N. (2014). Genetic visualization with GENVISIS. Manuscript in
preparation.
Price, A. L., Kryukov, G. V., de Bakker, P. I., Purcell, S. M., Staples, J., Wei,
L. J., & Sunyaev, S. R. (2010). Pooled association tests for rare variants
in exon-resequencing studies. American Journal of Human Genetics,
86, 832–838. doi: 10.1016/j.ajhg.2010.04.005
Rangaswamy, M., Porjesz, B., Chorlian, D. B., Choi, K., Jones, K. A.,
Wang, K., . . . Begleiter, H. (2003). Theta power in the EEG of alco-
holics. Alcoholism, Clinical and Experimental Research, 27, 607–615.
doi: 10.1097/01.ALC.0000060523.95470.8F
Richardson, R. J., Hein, N. D., Wijeyesakere, S. J., Fink, J. K., &
Makhaeva, G. F. (2013). Neuropathy target esterase (NTE): Overview
and future. Chemico-Biological Interactions, 203, 238–244. doi:
10.1016/j.cbi.2012.10.024
Sponheim, S. R., Clementz, B. A., Iacono, W. G., & Beiser, M. (1994).
Resting EEG in first-episode and chronic schizophrenia.
Psychophysiology, 31, 37–43.
Sponheim, S. R., Clementz, B. A., Iacono, W. G., & Beiser, M. (2000).
Clinical and biological concomitants of resting state EEG power abnor-
malities in schizophrenia. Biological Psychiatry, 48, 1088–1097.
Sponheim, S. R., Iacono, W. G., Thuras, P. D., Nugent, S. M., & Beiser, M.
(2003). Sensitivity and specificity of select biological indices in char-
acterizing psychotic patients and their relatives. Schizophrenia
Research, 63, 27–38.
Stein, J. L., Medland, S. E., Vasquez, A. A., Hibar, D. P., Senstad, R. E.,
Winkler, A. M., . . . Thompson, P. M. (2012). Identification of common
variants associated with human hippocampal and intracranial volumes.
Nature Genetics, 44, 552–561.
Struve, F. A., Straumanis, J. J., Patrick, G., Leavitt, J., Manno, J. E., &
Manno, B. R. (1999). Topographic quantitative EEG sequelae of
chronic marihuana use: A replication using medically and psychiatri-
cally screened normal subjects. Drug and Alcohol Dependence, 56,
167–179.
Tennessen, J. A., Bigham, A. W., O’Connor, T. D., Fu, W., Kenny, E. E.,
Gravel, S., . . . NHLBI Exome Sequencing Project. (2012). Evolution
and functional impact of rare coding variation from deep sequencing of
human exomes. Science, 337, 64–69. doi: 10.1126/science.1219240
Thompson, P. M., Stein, J. L., Medland, S. E., Hibar, D. P., Vasquez, A. A.,
Renteria, M. E., . . . Drevets, W. (2014). The ENIGMA Consortium:
Large-scale collaborative analyses of neuroimaging and genetic data.
Brain Imaging and Behavior, 1–30. doi: 10.1007/s11682-013-9269-5
Vaidyanathan, U., Isen, J. D., Malone, S. M., Miller, M. B., McGue, M., &
Iacono, W. G. (2014). Heritability and molecular genetic basis
of electrodermal activity: A genome-wide association study.
Psychophysiology, 51, 1259–1271.
Vaidyanathan, U., Malone, S. M., Donnelly, J. M., Hammer, M. A., Miller,
M. B., McGue, M., & Iacono, W. G. (2014). Heritability and molecular
genetic basis of antisaccade eye tracking error rate: A genome-wide
association study. Psychophysiology, 51, 1272–1284.
Exomes and endophenotypes 1307
Vaidyanathan, U., Malone, S. M., Miller, M. B., McGue, M., & Iacono,
W. G. (2014). Heritability and molecular genetic basis of acoustic
startle eye blink and affectively modulated startle response: A
genome-wide association study. Psychophysiology, 51, 1285–1299.
Vrieze, S. I., Malone, S. M., Vaidyanathan, U., Kwong, A., Kang, H. M.,
Zhan, X., . . . Iacono, W. G. (2014). In search of rare variants: Prelimi-
nary results from whole genome sequencing of 1,325 individuals with
psychophysiological endophenotypes. Psychophysiology, 51, 1309–
1320.
Wilson, P. A., Gardner, S. D., Lambie, N. M., Commans, S. A., & Crowther,
D. J. (2006). Characterization of the human patatin-like phospholipase
family. Journal of Lipid Research, 47, 1940–1949. doi: 10.1194/
jlr.M600185-JLR200
Wu, M. C., Lee, S., Cai, T. X., Li, Y., Boehnke, M., & Lin, X. H. (2011).
Rare-variant association testing for sequencing data with the sequence
kernel association test. American Journal of Human Genetics, 89,
82–93. doi: 10.1016/j.ajhg.2011.05.029
Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Table S1: Why markers were flagged, reclustered, or dropped.
Table S2: Final counts for each manual annotation category.
Table S3: Correlation matrix of residualized phenotypes.
Figures S1–S17: QQ and Manhattan plots of association results
from all 17 endophenotypes.
1308 S.I. Vrieze et al.
